Chemical Property of Mirabegron
Chemical Property:
- Appearance/Colour:Light yellow to yellow solid
- Vapor Pressure:5.45E-20mmHg at 25°C
- Melting Point:138-140 °C
- Refractive Index:1.68
- Boiling Point:690.008 °C at 760 mmHg
- PKA:13.51±0.70(Predicted)
- Flash Point:371.104 °C
- PSA：128.51000
- Density:1.314 g/cm3
- LogP:3.81730
- Storage Temp.:-20°C Freezer
- Solubility.:Chloroform (Slightly, Heated), Methanol (Slightly)
- XLogP3:2.1
- Hydrogen Bond Donor Count:4
- Hydrogen Bond Acceptor Count:6
- Rotatable Bond Count:9
- Exact Mass:396.16199719
- Heavy Atom Count:28
- Complexity:467
- Purity/Quality:
-
99% *data from raw suppliers
Mirabegron *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
SDS file from LookChem
Useful:
- Drug Classes:Urologic Agents
- Canonical SMILES:C1=CC=C(C=C1)C(CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O
- Isomeric SMILES:C1=CC=C(C=C1)[C@H](CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O
- Recent ClinicalTrials:Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity
- Recent EU Clinical Trials:β3 adrenergic agoniSt treatment in chronic Pulmonary HypERtEnsion secondary to heart failure: a randomized placebo-controlled phase 2 clinical trial
- Recent NIPH Clinical Trials:The safety and effectiveness of mirabegron in Parkinson's disease patients with overactive bladder
-
Description
Betanis (Mirabegron) was approved in July 2011 by the Japanese
Ministry of Health, Labour, and Welfare for the treatment of urgency,
urinary frequency, and urinary urge urinary incontinence associated with
overactive bladder (OAB).
Mirabegron is synthesized by coupling 4-nitrophenethyl amine to (R)-2-hydroxy-2-phenylacetic acid. The resulting amide is reduced to an amine. The nitro group is then
reduced and the resulting aniline is coupled to 2-(2-aminothiazol-4-yl)
acetic acid to give mirabegron. Mirabegron has an EC50 of 22 nM (intrinsic activity=0.8) for β3-AR with no detectable activity for β1- andβ2-AR (EC50>10,000 nM). In an anesthetized rat rhythmic bladder
contraction model in which bladder contractions are induced by saline,
mirabegron at 3 mg/kg iv decreased the frequency of rhythmic bladder
contraction without suppressing contraction amplitude. These data suggest
that the activation of β3-AR increases bladder capacity without
influencing the frequency of bladder contraction.
-
Uses
Mirabegron is a selective β3-adrenoceptor agonist with EC50 of 22.4 nM. A potent bladder relaxant compound Potent bladder relaxant and reagent for diabetes remedy.;Labeled Mirabegron, intended for use as an internal standard for the quantification of Mirabegron by GC- or LC-mass spectrometry.
-
Clinical Use
Mirabegron is an orally active β3-adrenoceptor agonist currently
in development by Astellas Pharma for the treatment of overactive
bladder (OAB). The drug is a nanomolar EC50 antagonist against human
β3-AR biochemical assays with good selectivity over b1- and
β2-ARs. Mirabegron demonstrates a novel mechanism by targeting
the β3-AR for bladder relaxation to help manage OAB symptoms
such as increased urinary urgency and frequency and urgency incontinence.
However, mirabegron is a cytochrome P450 2D6 inhibitor,
and it raises a concern for drug–drug interaction with concomitant
administration of other cytochrome P450 2D6 substrates.
-
Drug interactions
Potentially hazardous interactions with other drugs
None known
